Park Avenue Securities’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.9M | Sell |
98,903
-4,948
| -5% | -$1.06M | 0.16% | 109 |
|
|
2026
Q1 | $22.6M | Sell |
103,851
-4,584
| -4% | -$1.02M | 0.18% | 97 |
|
|
2025
Q4 | $24.8M | Sell |
108,435
-1,422
| -1% | -$324K | 0.21% | 82 |
|
|
2025
Q3 | $25.4M | Buy |
109,857
+6,068
| +6% | +$1.24M | 0.2% | 82 |
|
|
2025
Q2 | $19.3M | Buy |
+103,789
| New | +$19.3M | 0.18% | 94 |
|
|
2025
Q1 | – | Sell |
-87,664
| Closed | -$15.6M | – | 1158 |
|
|
2024
Q4 | $15.6M | Buy |
87,664
+18,379
| +27% | +$3.38M | 0.16% | 96 |
|
|
2024
Q3 | $13.7M | Sell |
69,285
-10,402
| -13% | -$1.94M | 0.15% | 98 |
|
|
2024
Q2 | $13.7M | Buy |
79,687
+1,803
| +2% | +$299K | 0.17% | 90 |
|
|
2024
Q1 | $14.2M | Buy |
77,884
+1,836
| +2% | +$316K | 0.18% | 78 |
|
|
2023
Q4 | $11.8M | Buy |
76,048
+925
| +1% | +$135K | 0.16% | 87 |
|
|
2023
Q3 | $11.2M | Buy |
75,123
+3,603
| +5% | +$529K | 0.17% | 81 |
|
|
2023
Q2 | $9.64M | Sell |
71,520
-8,879
| -11% | -$1.3M | 0.15% | 95 |
|
|
2023
Q1 | $12.8M | Buy |
80,399
+9,491
| +13% | +$1.45M | 0.22% | 66 |
|
|
2022
Q4 | $11.5M | Buy |
70,908
+4,516
| +7% | +$692K | 0.2% | 72 |
|
|
2022
Q3 | $8.91M | Buy |
66,392
+6,452
| +11% | +$926K | 0.18% | 74 |
|
|
2022
Q2 | $9.18M | Sell |
59,940
-2,420
| -4% | -$370K | 0.18% | 69 |
|
|
2022
Q1 | $10.1M | Buy |
62,360
+4,403
| +8% | +$640K | 0.18% | 66 |
|
|
2021
Q4 | $7.85M | Buy |
57,957
+5,559
| +11% | +$657K | 0.14% | 88 |
|
|
2021
Q3 | $5.65M | Buy |
52,398
+1,915
| +4% | +$219K | 0.11% | 95 |
|
|
2021
Q2 | $5.69M | Buy |
50,483
+2,728
| +6% | +$307K | 0.12% | 86 |
|
|
2021
Q1 | $5.17M | Buy |
47,755
+7,370
| +18% | +$788K | 0.13% | 78 |
|
|
2020
Q4 | $4.33M | Buy |
40,385
+4,169
| +12% | +$401K | 0.12% | 72 |
|
|
2020
Q3 | $3.17M | Buy |
36,216
+1,212
| +3% | +$114K | 0.11% | 88 |
|
|
2020
Q2 | $3.44M | Buy |
35,004
+3,976
| +13% | +$350K | 0.13% | 71 |
|
|
2020
Q1 | $2.36M | Buy |
31,028
+8,914
| +40% | +$759K | 0.2% | 43 |
|
|
2019
Q4 | $1.96M | Buy |
22,114
+4,887
| +28% | +$406K | 0.08% | 104 |
|
|
2019
Q3 | $1.3M | Buy |
17,227
+1,890
| +12% | +$130K | 0.06% | 126 |
|
|
2019
Q2 | $1.11M | Buy |
15,337
+3,127
| +26% | +$246K | 0.12% | 63 |
|
|
2019
Q1 | $986K | Buy |
12,210
+1,870
| +18% | +$153K | 0.05% | 132 |
|
|
2018
Q4 | $913K | Buy |
10,340
+2,673
| +35% | +$235K | 0.14% | 51 |
|
|
2018
Q3 | $728K | Buy |
7,667
+290
| +4% | +$27.5K | 0.12% | 61 |
|
|
2018
Q2 | $687K | Buy |
7,377
+1,354
| +22% | +$132K | 0.12% | 56 |
|
|
2018
Q1 | $551K | Buy |
6,023
+2,718
| +82% | +$299K | 0.12% | 60 |
|
|
2017
Q4 | $325K | Sell |
3,305
-1,118
| -25% | -$105K | 0.08% | 77 |
|
|
2017
Q3 | $400K | Sell |
4,423
-476
| -10% | -$36.2K | 0.12% | 50 |
|
|
2017
Q2 | $351K | Buy |
+4,899
| New | +$329K | 0.04% | 112 |
|
|
2017
Q1 | – | Sell |
-3,710
| Closed | -$232K | – | 53 |
|
|
2016
Q4 | $232K | Buy |
3,710
+464
| +14% | +$28.3K | 0.11% | 45 |
|
|
2016
Q3 | $205K | Buy |
+3,246
| New | +$210K | 0.12% | 43 |
|
Other funds holding ABBV
Park Avenue Securities's ABBV Position: Q2 2026 in Review
Park Avenue Securities reduced its AbbVie (ABBV) stake by 4.8% in Q2 2026, selling an estimated $1.06M and leaving 98,903 shares worth $24.9M. The position accounts for 0.16% of the portfolio, ranked #109.
Park Avenue Securities first reported a position in ABBV in Q3 2016 and has held it in 38 quarters since. The position peaked at $25.4M in Q3 2025. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Park Avenue Securities held 98,903 shares of AbbVie worth $24.9M as of Q2 2026.
- Park Avenue Securities sold 4,948 AbbVie shares in Q2 2026, an estimated $1.06M.
- AbbVie made up 0.16% of Park Avenue Securities's portfolio in Q2 2026, its #109 holding.
- Park Avenue Securities first reported a position in AbbVie in Q3 2016 and has held it in 38 quarters since.
- Park Avenue Securities's AbbVie position peaked at $25.4M in Q3 2025.
- 4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.